$2.140
+0.041 (+1.90%)Al cierre
- High
- 2.150
- Open
- 2.130
- VWAP
- 2.10
- Vol
- 131.88K
- Mkt Cap
- 7.56M
- Low
- 2.010
- Amount
- 276.95K
- EV/EBITDA, TTM
- 0.00
Biomerica, Inc. is a biomedical technology company. The Company develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients in the diagnosis of various diseases, food intolerances, and other medical complications. The Company’s diagnostic test kits can also be used to measure or detect the presence and levels of specific bacteria, hormones, antibodies, antigens and other substances, which may exist in the human body in small concentrations. Its range of medical diagnostic products is sold in two markets: clinical laboratories and point-of-care settings. The Company’s diagnostic-guided therapy (DGT) product is developed on the inFoods technology platform, which is designed to aid in the management of gastrointestinal conditions such as irritable bowel syndrome (IBS) and other inflammatory diseases.
AI analysis of Biomerica Inc (BMRA)
buyBiomerica Inc (BMRA) is a good buy right now due to its recent price increase of 32.92% over the last five days, indicating strong momentum. Additionally, the stock is currently priced at $2.14, which is above its 200-day simple moving average of $2.132, suggesting a bullish trend. However, investors should be aware of the risk of dilution from the recent financing, which could impact existing shareholders as it represents about 30.4% of the pro forma shares outstanding.
Analyst Ratings (1)
Métricas de valoración
Cronología de eventos
Noticias
8.508-27NASDAQ.COMBiomerica Secures $2.23 Million Financing to Stabilize Operations
8.508-27NewsfilterBiomerica Secures $2.23 Million Financing at $1.60 per Share
- 8.504-29Newsfilter
Biomerica to Present IBS Therapy at Digestive Disease Week 2026
- 8.504-16Newsfilter
Biomerica's IBS Test Receives Medicare Coverage Confirmation
9.504-14NASDAQ.COMBiomerica Reports Decline in Q3 Revenue Amid Restructuring Efforts
BMRA FAQ — answered by Alphio AI
Biomerica, Inc. is a biomedical technology company. The Company develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients in the diagnosis of various diseases, food intolerances, and other medical complications. The Company’s diagnostic test kits can also be used to measure or detect the presence and levels of specific bacteria, hormones, antibodies, antigens and other substances, which may exist in the human body in small concentrations. Its range of medical diagnostic products is sold in two markets: clinical laboratories and point-of-care settings. The Company’s diagnostic-guided therapy (DGT) product is developed on the inFoods technology platform, which is designed to aid in the management of gastrointestinal conditions such as irritable bowel syndrome (IBS) and other inflammatory diseases. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).
Biomerica Inc (BMRA) is a good buy right now due to its recent price increase of 32.92% over the last five days, indicating strong momentum. Additionally, the stock is currently priced at $2.14, which is above its 200-day simple moving average of $2.132, suggesting a bullish trend. However, investors should be aware of the risk of dilution from the recent financing, which could impact existing shareholders as it represents about 30.4% of the pro forma shares outstanding.
1 analysts cover BMRA: 1 rate it Buy, 0 Hold and 0 Sell.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.